Oramed Announces End-of-Phase 2 Meeting with FDA to Initiate Phase 3 Program

JERUSALEM, July 11, 2017 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the U.S. Food and Drug Administration (FDA) has agreed to schedule an End-of-Phase II meeting with Oramed for its successfully completed Phase IIb trial of its oral […]

Join our mailing list

Skip to content